A linear relationship has been suggested between increasing pCR rate and increasing recurrence-free survival.39 A meta-analysis by Cortazar et al included 11 955 patients from 12 randomized clinical trials and showed that NAC significantly improved the pCR rate and event-free survival compared with ACT.40 Meanwhile, the association between pCR and long-term outcomes was strongest in patients with aggressive tumor subtypes, such as TNBC and HER2-positive, and hormone receptor-negative tumors. The gene discussed is ERBB2; the disease is neoplasm.